Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 14 studies | 25% ± 9% | |
microglial cell | 11 studies | 30% ± 12% | |
astrocyte | 11 studies | 33% ± 16% | |
oligodendrocyte | 8 studies | 27% ± 9% | |
oligodendrocyte precursor cell | 7 studies | 29% ± 12% | |
macrophage | 7 studies | 33% ± 12% | |
epithelial cell | 6 studies | 28% ± 12% | |
dendritic cell | 6 studies | 21% ± 4% | |
ciliated cell | 6 studies | 25% ± 7% | |
T cell | 6 studies | 23% ± 8% | |
CD8-positive, alpha-beta T cell | 5 studies | 18% ± 2% | |
adipocyte | 5 studies | 22% ± 3% | |
myeloid cell | 5 studies | 24% ± 8% | |
endothelial cell of lymphatic vessel | 5 studies | 23% ± 4% | |
monocyte | 5 studies | 24% ± 7% | |
CD8-positive, alpha-beta memory T cell | 4 studies | 17% ± 1% | |
neuron | 4 studies | 40% ± 21% | |
lymphocyte | 4 studies | 30% ± 10% | |
GABAergic neuron | 4 studies | 45% ± 17% | |
glutamatergic neuron | 4 studies | 56% ± 21% | |
fibroblast | 4 studies | 20% ± 3% | |
interneuron | 4 studies | 36% ± 22% | |
classical monocyte | 3 studies | 16% ± 0% | |
plasma cell | 3 studies | 25% ± 10% | |
CD4-positive, alpha-beta T cell | 3 studies | 21% ± 3% | |
mononuclear phagocyte | 3 studies | 21% ± 6% | |
retinal rod cell | 3 studies | 18% ± 2% | |
ependymal cell | 3 studies | 32% ± 17% | |
alveolar macrophage | 3 studies | 29% ± 11% | |
pericyte | 3 studies | 19% ± 3% | |
type I pneumocyte | 3 studies | 20% ± 4% | |
goblet cell | 3 studies | 28% ± 13% | |
transit amplifying cell | 3 studies | 31% ± 20% | |
smooth muscle cell | 3 studies | 17% ± 2% | |
plasmacytoid dendritic cell | 3 studies | 18% ± 2% | |
mast cell | 3 studies | 22% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 2189.84 | 578 / 578 | 100% | 14.86 | 1153 / 1155 |
esophagus | 100% | 2352.94 | 1445 / 1445 | 99% | 21.08 | 182 / 183 |
intestine | 100% | 2388.40 | 966 / 966 | 99% | 13.29 | 520 / 527 |
breast | 100% | 2184.64 | 459 / 459 | 98% | 15.92 | 1101 / 1118 |
thymus | 100% | 2237.84 | 653 / 653 | 98% | 12.10 | 595 / 605 |
stomach | 100% | 1688.65 | 359 / 359 | 98% | 15.57 | 281 / 286 |
ovary | 100% | 1590.06 | 180 / 180 | 98% | 10.87 | 422 / 430 |
brain | 100% | 1329.09 | 2631 / 2642 | 98% | 11.17 | 691 / 705 |
kidney | 100% | 1680.88 | 89 / 89 | 97% | 14.08 | 872 / 901 |
skin | 100% | 2748.40 | 1809 / 1809 | 96% | 14.90 | 453 / 472 |
uterus | 100% | 2096.20 | 170 / 170 | 96% | 10.62 | 440 / 459 |
pancreas | 100% | 1146.96 | 327 / 328 | 96% | 10.31 | 171 / 178 |
bladder | 100% | 2328.48 | 21 / 21 | 95% | 10.21 | 481 / 504 |
prostate | 100% | 1764.86 | 245 / 245 | 93% | 9.45 | 467 / 502 |
adrenal gland | 100% | 2373.47 | 258 / 258 | 85% | 6.62 | 196 / 230 |
liver | 99% | 941.08 | 223 / 226 | 72% | 5.13 | 293 / 406 |
adipose | 100% | 2314.77 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2210.87 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 10.18 | 29 / 29 |
muscle | 100% | 2184.49 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2269.50 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 14.44 | 44 / 45 |
heart | 96% | 1441.09 | 826 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 91% | 1587.11 | 849 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 85% | 7.67 | 68 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0035360 | Biological process | positive regulation of peroxisome proliferator activated receptor signaling pathway |
GO_0045600 | Biological process | positive regulation of fat cell differentiation |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0009887 | Biological process | animal organ morphogenesis |
GO_0035517 | Cellular component | PR-DUB complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0003677 | Molecular function | DNA binding |
GO_0042975 | Molecular function | peroxisome proliferator activated receptor binding |
GO_0003682 | Molecular function | chromatin binding |
GO_0046872 | Molecular function | metal ion binding |
Gene name | ASXL2 |
Protein name | ASXL transcriptional regulator 2 Putative Polycomb group protein ASXL2 (Additional sex combs-like protein 2) |
Synonyms | KIAA1685 ASXH2 |
Description | FUNCTION: Putative Polycomb group (PcG) protein. PcG proteins act by forming multiprotein complexes, which are required to maintain the transcriptionally repressive state of homeotic genes throughout development. PcG proteins are not required to initiate repression, but to maintain it during later stages of development. They probably act via methylation of histones, rendering chromatin heritably changed in its expressibility (By similarity). Involved in transcriptional regulation mediated by ligand-bound nuclear hormone receptors, such as peroxisome proliferator-activated receptor gamma (PPARG). Acts as coactivator for PPARG and enhances its adipocyte differentiation-inducing activity; the function seems to involve differential recruitment of acetylated and methylated histone H3. . |
Accessions | E7EWD6 A0A5F9ZH08 ENST00000673455.1 ENST00000435504.9 [Q76L83-1] ENST00000404843.5 [Q76L83-2] Q76L83 ENST00000672666.1 ENST00000336112.9 A0A5F9ZHN2 ENST00000497092.1 A0A5F9ZHC8 |